Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma (Q51012672)
scientific article published on 9 December 2003
Language:
Current Data About Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma
(P31) (Q13442814)
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

(P50) (Q32649737)
(P1545) 9
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

(P304) 53-61
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

(P407) (Q1860)

(P433) 1
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

(P478) 22
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

(P577) Tuesday, December 9, 2003
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

(P1433) (Q400292)
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

(P1476) "Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma" (language: en)
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

(P2093) Hancock BW
(P1545) 1
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Wheatley K
(P1545) 2
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Harris S
(P1545) 3
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Ives N
(P1545) 4
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Harrison G
(P1545) 5
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Horsman JM
(P1545) 6
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Middleton MR
(P1545) 7
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Thatcher N
(P1545) 8
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Marsden JR
(P1545) 10
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Burrows L
(P1545) 11
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

Gore M
(P1545) 12
(P248)
(P698) 14665609
(P813) Tuesday, March 27, 2018
(P854) http://europepmc.org/abstract/MED/14665609

other details
description scientific article published on 9 December 2003

External Links
(P356) 10.1200/JCO.2004.03.185
(P698) 14665609